DP
HRTX icon

Diadema Partners’s Heron Therapeutics HRTX Stock Holding History

Diadema Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$196K Buy
+458,723
New +$368K 0.02% 129

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Diadema Partners's HRTX Position: Q2 2026 in Review

Diadema Partners opened a new position in Heron Therapeutics (HRTX) in Q2 2026: 458,723 shares worth $196K. The stake represents 0.02% of the portfolio and ranks #129 among its holdings.

162 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Diadema Partners held 458,723 shares of Heron Therapeutics worth $196K as of Q2 2026.
  • Heron Therapeutics was a new Diadema Partners position in Q2 2026.
  • Heron Therapeutics made up 0.02% of Diadema Partners's portfolio in Q2 2026, its #129 holding.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.